International Stem Cell Corp Announces World-Renowned Scientists Join as Advisors on Parkinson's Disease Program
August 16 2012 - 8:00AM
Marketwired
International Stem Cell Corporation (OTCQB: ISCO)
(www.internationalstemcell.com) ("ISCO" or "the Company") a
California-based biotechnology company focused on therapeutic and
research products, today announced the addition of Professor Evan
Snyder* and Dr. Rosasio Sánchez-Pernaute as scientific advisors on
our Parkinson's disease program.
Evan Snyder, MD, PhD is a Professor at the Sanford-Burnham
Medical Research Institute and director of Sanford-Burnham's stem
cell program and research center. Prof. Snyder is regarded as one
of the pioneers of stem cell research, particularly with regard to
regenerative medicine applications. He is an expert on Parkinson's
disease (PD), one of the first scientists to identify neural stem
cells and to document the ability of stem cells to migrate to
injured or diseased regions of the brain. Prof. Snyder is a
recipient of an Early Translational Award from the California
Institute for Regenerative Medicine (CIRM) to research into cell
based therapies for PD.
Rosario Sánchez-Pernaute, MD, PhD is an internationally
recognized expert on the use of stem cells to treat Parkinson's
disease. While Assistant Professor in Neurology at Harvard Medical
School Dr. Sánchez-Pernaute was one of the first scientists to
demonstrate the possibility of using parthenogenetic stem cells to
treat the causes of PD in a non-human primate model.
"We are extremely fortunate to work with two of the world's
leading experts in Parkinson's disease and stem cell research," say
Dr. Ruslan Semechkin, Vice President of Research and Development,
"Prof. Snyder and Dr. Sánchez-Pernaute will add invaluable
expertise to our Parkinson's disease program and provide input into
our first non-human primate pre-clinical study which uses the most
reliable and predictive model of Parkinson's in humans."
*Prof. Snyder's position is honorary.
About International Stem Cell
Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues
associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenetic, homozygous
stem cell line that can be a source of therapeutic cells for
hundreds of millions of individuals of differing genders, ages and
racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products
through its subsidiary Lifeline Skin Care
(www.lifelineskincare.com). More information is available at
www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please
click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
Safe harbor statement
Statements pertaining to anticipated developments, scientific
program and clinical development goals and plans and other
opportunities for the company and its subsidiaries, along with
other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as "will," "believes," "plans," "anticipates," "expects,"
"estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products and the
management of collaborations, regulatory approvals, need and
ability to obtain future capital, application of capital resources
among competing uses, and maintenance of intellectual property
rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should
be evaluated together with the many uncertainties that affect the
company's business, particularly those mentioned in the cautionary
statements found in the company's Securities and Exchange
Commission filings. The company disclaims any intent or obligation
to update forward-looking statements.
Contacts: International Stem Cell Corporation Dr. Simon
Craw Executive Vice President Phone: 760-940-6383 Email: Email
Contact Investor Relations: MZ Group Mark McPartland Senior Vice
President Phone: 212-301-7130 Email: Email Contact Web:
www.mzgroup.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jul 2023 to Jul 2024